SCHEMBL7724120

SCHEMBL7724120

Cc1cc(F)c(C)cc1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.55
MAPT P10636 2/20 0.55
ALDH1A1 P00352 1/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2D6 P10635 1/20 0.55
G6PD P11413 1/20 0.55
CYP2C9 P11712 1/20 0.55
PKM P14618 1/20 0.55
HPGD P15428 1/20 0.55
ALOX15 P16050 1/20 0.55
ALOX12 P18054 1/20 0.55
MAPK1 P28482 1/20 0.55
CYP2C19 P33261 1/20 0.55
CCR6 P51684 1/20 0.55
HIF1A Q16665 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
HSD17B10 Q99714 1/20 0.55
TP53 P04637 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL765876 0.89 KDM4E (0.48) KDM4EMAPTALDH1A1CYP1A2CYP3A4
SCHEMBL6461901 0.86 KDM4E (0.50) KDM4EMAPTALDH1A1CYP1A2CYP3A4
SCHEMBL13090168 0.86 KDM4E (0.43) KDM4EMAPTALDH1A1CYP1A2CYP3A4
SCHEMBL6438897 0.83 KDM4E (0.48) KDM4EMAPTALDH1A1CYP1A2CYP3A4
SCHEMBL29940515 0.83 MAPT (0.42) KDM4EMAPTALDH1A1CYP1A2CYP3A4
SCHEMBL30626637 0.83 CA3 (0.40) KDM4EMAPTALDH1A1CYP1A2CYP3A4
SCHEMBL14783939 0.83 MAPT (0.42) KDM4EMAPTALDH1A1CYP1A2CYP3A4
SCHEMBL6744533 0.83 CA3 (0.40) KDM4EMAPTALDH1A1CYP1A2CYP3A4
SCHEMBL70123 0.82 MAPT (0.75) KDM4EMAPTALDH1A1CYP1A2CYP3A4
SCHEMBL261036 0.82 ACHE (0.42) ALDH1A1CYP3A4MAPK1TP53TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-02-23 US disclosed
US-20220119333-A1 PHENOXY ACID COMPOUNDS AND MEDICAL USES THEREOF QINGDAO WHOLESOMTECH CO., LTD. (CN) 2022-04-21 US disclosed
WO-2021228034-A1 PREPARATION METHOD OF (5-FLUORO-2, 3-DIHYDROBENZOFURAN-4-YL) METHANAMINE OR ITS SALT, AND INTERMEDIATES THEREOF ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2021-11-18 WO disclosed
EP-3842410-A1 FIBRIC ACID COMPOUND AND MEDICAL USE THEREOF Beijing Wholesomeyird Sci & Tech Co., Ltd. (CN) 2021-06-30 EP disclosed
US-20210130337-A1 Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists KING'S COLLEGE LONDON (GB) 2021-05-06 US disclosed
US-20210085796-A1 ANTICANCER DRUGS AND METHODS OF MAKING AND USING SAME YALE UNIVERSITY 2021-03-25 US disclosed
US-10752616-B2 Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists KING'S COLLEGE LONDON (GB) 2020-08-25 US disclosed
US-20200131165-A1 Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists KING'S COLLEGE LONDON (GB) 2020-04-30 US disclosed
WO-2020038464-A1 FIBRIC ACID COMPOUND AND MEDICAL USE THEREOF 北京厚燊药德科技有限责任公司 2020-02-27 WO disclosed
US-10385044-B2 Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists KING'S COLLEGE LONDON (GB) 2019-08-20 US disclosed
EP-2688980-B1 MESOGEN COMPOUNDS, LIQUID CRYSTALLINE MEDIA AND COMPONENTS FOR HIGH FREQUENCY TECHNOLOGY MERCK PATENT GMBH (DE) 2016-11-02 EP disclosed
WO-2016097004-A1 BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARβ) AGONISTS KING'S COLLEGE LONDON (GB) 2016-06-23 WO disclosed
US-20150148430-A1 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS TANSNA THERAPEUTICS, INC. 2015-05-28 US disclosed
US-20150148430-A1 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS TANSNA THERAPEUTICS, INC. 2015-05-28 US disclosed
US-20150148430-A1 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS TANSNA THERAPEUTICS, INC. 2015-05-28 US disclosed
EP-1751139-B1 SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER BAYER HEALTHCARE LLC (US) 2011-07-27 EP disclosed
US-6358995-B1 AGONIST FOR RETINOIC ACID RECEPTORS; CAN BE SUBSTITUTED FOR RETINOIC ACID AS PREVENTIVE AND THERAPEUTIC DRUGS FOR VARIOUS DISEASES OR CANCERS, SUCH AS ACUTE PROMYELOCYTIC LEUKEMIA. EISAI CO., LTD. (JP) 2002-03-19 US disclosed
US-6121309-A SUCH AS 4-(2-(5-(7-FLUORO-4-TRIFLUOROMETHYLBENZOFURAN-2-YL)PYRROLYL)) BENZOIC ACID; RETINOIC ACID RECEPTOR AGONISM EISAI CO., LTD. (JP) 2000-09-19 US disclosed
US-6110959-A A RETINOIC ACID RECEPTOR AGONIST EISAI CO., LTD. (JP) 2000-08-29 US disclosed
EP-0889032-A1 FUSED-RING CARBOXYLIC ACID DERIVATIVES Eisai Co., Ltd. (JP) 1999-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210130337-A1 Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists RARB, RARA, RXRB KDM4E 3575/4885MAPT 2263/4885ALDH1A1 253/4885
US-20210085796-A1 ANTICANCER DRUGS AND METHODS OF MAKING AND USING SAME MTHFD1, DHFR, ABCG2 KDM4E 824/4885MAPT 2162/4885ALDH1A1 469/4885
US-20200131165-A1 Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists RARB, RARA, RXRB KDM4E 3575/4885MAPT 2263/4885ALDH1A1 253/4885
US-20220119333-A1 PHENOXY ACID COMPOUNDS AND MEDICAL USES THEREOF PYGL, SLC10A1, GYS2 KDM4E 2937/4885MAPT 439/4885ALDH1A1 868/4885
US-20150148430-A1 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS COMT, DDT, TYR KDM4E 303/4885MAPT 259/4885ALDH1A1 852/4885
US-10385044-B2 Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists RARB, RARA, RARG KDM4E 3651/4885MAPT 2291/4885ALDH1A1 239/4885
US-10752616-B2 Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists RARB, RARA, RXRB KDM4E 3621/4885MAPT 2234/4885ALDH1A1 238/4885
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 KDM4E 2544/4885MAPT 1932/4885ALDH1A1 3964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.